Over the last century, eosinophils have been regarded ambiguously either as ‘friends’ or ‘foes’. Recent developments have greatly enhanced our understanding of the role and function of eosinophils in health and disease. Pathogenic eosinophilic inflammation can lead to severe diseases in various organs, such as the gastrointestinal tract, airways, heart and skin. In a 2-day focus workshop of the German Society for Allergology and Clinical Immunology (DGAKI), the state of the art was discussed and practical recommendations for diagnosis and treatment of eosinophilic diseases, with a particular focus on new biologics, such as anti-interleukin 5 and anti-interleukin 5R, were derived.
Bibliographical noteFunding Information:
Harald Renz was funded by the Universities Giessen Marburg Lung Center and the German Center for Lung Disease (DZL German Lung Center, no. 82DZL00502) for UGMLC. Claus Bachert was supported by grants from the European Commission?s Seventh Framework Program under grant agreement No. 260895 (PREDICTA), the Flemish Scientific Research Board (Research Foundation-Flanders, projects 1841713N, G.039412N, G.067512N, and BOF14/GOA/019), and the Interuniversity Attraction Poles Program of the Belgian State Science Policy Office (No. IAP P7/30) (C.B.); The study was supported in part by the Austrian Science Fund (FWF) grant SFB F47-B20 to Peter Valent. Eckard Hamelmann was funded by the German Ministry of Education and Research (BMBF: 01GL1742D CHAMP). David Voehringer was funded by the DFG grant Vo944/9-1 to D.V. Ulrike Raap was funded by the DFG RA 1026 3-1. Johannes Ring and Sabine Ploetz were supported by the Christine Kuehne Center for Allergy Research and Education (CK-CARE), Davos, Switzerland. Thomas Werfel was funded by Hanover Medical University, by the DFG cluster of excellence RESIST and by DFG grant WeXXX. Open Access funding enabled and organized by Projekt DEAL.WOA Institution: PHILIPPS-UNIVERSITAET MARBURGBlended DEAL: Projekt DEAL.
© 2021 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.
- DNAzyme against GATA3; eosinophil
- anti-interleukin 5
- eosinophil diseases
- hypereosinophilic syndrome
- interleukin 5
- DNAzyme against GATA3